Comparison of clinical outcomes from baseline analysis of the two screening approaches in a general screening population.

NIPT, non-invasive prenatal testing
* 70% of total affected pregnancies (30% receive no screening).
† Assuming termination rates for trisomy 21, trisomy 18, trisomy 13, and monosomy X of 87%, 81%, 90%, and 65%, respectively [34]; excludes spontaneous fetal losses.
‡ Invasive tests (amniocentesis or chorionic villus sampling) performed in true positives and false positives.
Comparison of clinical outcomes from baseline analysis of the two screening approaches in a general screening population.